| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/07/2009 | CA2463294C Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 04/07/2009 | CA2458684C Pyrrolo pyrimidines as agents for the inhibition of cystein proteases |
| 04/07/2009 | CA2430814C A process for the preparation of paclitaxel |
| 04/07/2009 | CA2413190C Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 04/07/2009 | CA2377147C New indolocarbazole alkaloids from a marine actinomycete |
| 04/07/2009 | CA2352505C Epothilone derivatives and their use as antitumor agents |
| 04/07/2009 | CA2341968C Pyrrolobenzodiazepine compounds |
| 04/07/2009 | CA2341471C Pyrrolbenzodiazepines |
| 04/07/2009 | CA2339253C Inhibitors of p38 |
| 04/07/2009 | CA2312767C Drug delivery system with two-step targeting |
| 04/07/2009 | CA2269060C Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
| 04/07/2009 | CA2237157C Cyclopeptolide inhibitors of adhesion molecules |
| 04/07/2009 | CA2206343C Reagents and processes for targeting mutant epidermal growth factor receptors |
| 04/02/2009 | WO2009043051A2 Cd23 binding molecules and methods of use thereof |
| 04/02/2009 | WO2009042809A1 Stable imatinib compositions |
| 04/02/2009 | WO2009042803A1 Imatinib compositions |
| 04/02/2009 | WO2009042746A1 Novel antibodies |
| 04/02/2009 | WO2009042607A1 Thiazolopyrimidine p13k inhibitor compounds and methods of use |
| 04/02/2009 | WO2009042544A1 Quinone derivatives, pharmaceutical compositions, and uses thereof |
| 04/02/2009 | WO2009042542A1 Benzoquinone derivative e3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis |
| 04/02/2009 | WO2009041714A1 External preparation for free radical diseases |
| 04/02/2009 | WO2009041573A1 Use of anti-cancer cell composition for treatment of head and neck cancer, which is intended to be administered to nutrient artery of tumor |
| 04/02/2009 | WO2009041570A1 Polymer conjugate of steroid |
| 04/02/2009 | WO2009041521A1 Quinolone derivative |
| 04/02/2009 | WO2009041447A1 5-membered heterocyclic compound |
| 04/02/2009 | WO2009041062A1 Anti-glypican-3 antibody having improved kinetics in plasma |
| 04/02/2009 | WO2009040819A2 DOWN-REGULATION OF MORTALIN BY siRNA |
| 04/02/2009 | WO2009040817A2 Salarins and tulearins, compositions and uses thereof |
| 04/02/2009 | WO2009040556A1 Pyrimidine derivatives as protein kinase inhibitors |
| 04/02/2009 | WO2009040456A1 Novel chemotherapeutic agents for treating cancer |
| 04/02/2009 | WO2009040426A1 Immunoliposomes for treatment of cancer |
| 04/02/2009 | WO2009040418A1 Use of soluble ceacam8 for diagnosing, treating or monitoring diseases, and a method for screening compounds that prevent apoptosis |
| 04/02/2009 | WO2009040411A1 Photodynamic therapy and diagnosis using a chlorin e4 zinc complex |
| 04/02/2009 | WO2009040399A1 Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
| 04/02/2009 | WO2009040134A1 Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| 04/02/2009 | WO2009040089A2 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents |
| 04/02/2009 | WO2009040088A1 Use of peptide kvlpvpq as a therapeutic agent |
| 04/02/2009 | WO2009040086A2 Use of salusin-alpha as a therapeutic agent |
| 04/02/2009 | WO2009040085A2 Use of exendin-4 and optionally salusin-alpha as therapeutic agent(s) |
| 04/02/2009 | WO2009040084A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040083A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040073A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040072A2 Use of angiotensin i as a therapeutic agent in the treatment of eg aids or tuberculosis |
| 04/02/2009 | WO2009040071A2 Use of cyclo-rgdfv and optionally angiotensin i as therapeutic agents in the treatment of eg aids or tuberculosis |
| 04/02/2009 | WO2009040070A2 Use of helodermin as a therapeutic agent |
| 04/02/2009 | WO2009040068A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040067A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040051A2 Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent |
| 04/02/2009 | WO2009040050A2 Use of calcitonin as anti-angiogenic agent |
| 04/02/2009 | WO2009040049A2 Use of acetyl- (ala10, 11)-rantes (1-14) and/or calcitonin as anti-angiogenic agents |
| 04/02/2009 | WO2009040047A2 Therapeutic uses of ghrelin and combinations with stresscopin |
| 04/02/2009 | WO2009040046A2 Use of stresscopin-related peptide as a therapeutic agent |
| 04/02/2009 | WO2009040045A2 Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents |
| 04/02/2009 | WO2009040035A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040034A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040033A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040032A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040031A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040030A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040029A2 Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis |
| 04/02/2009 | WO2009040028A2 Use of casoxin c and optionally adrenomedullin as therapeutic agents for the treatment of excessive angiogenesis |
| 04/02/2009 | WO2009040027A1 Use of the peptide stresscopin as a therapeutic agent |
| 04/02/2009 | WO2009040025A2 Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent |
| 04/02/2009 | WO2009040024A2 Use of bim-23127 and optionally urodilatin as therapeutic agents eg for the treatment of m. tuberculosis infections |
| 04/02/2009 | WO2009040023A2 Use of galnon as a therapeutic agent |
| 04/02/2009 | WO2009040022A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040021A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040020A1 Amylin as a therapeutic agent |
| 04/02/2009 | WO2009040019A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040018A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040017A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040006A1 Spantide for therapeutic uses |
| 04/02/2009 | WO2009040005A2 Use of the peptide rfmwmr as a therapeutic agent |
| 04/02/2009 | WO2009040004A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039996A2 Use of bradykinin alone or in combination with melanotan ii as a therapeutic agent |
| 04/02/2009 | WO2009039995A1 Big gastrin i as a therapeutic agent |
| 04/02/2009 | WO2009039994A1 Proadrenomedullin alone or in combination with big gastrin i as a therapeutic agent |
| 04/02/2009 | WO2009039993A2 Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 04/02/2009 | WO2009039992A2 Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 04/02/2009 | WO2009039991A2 Use of aviptadil as a therapeutic agent |
| 04/02/2009 | WO2009039990A2 Use of icam peptide as a therapeutic agent |
| 04/02/2009 | WO2009039989A1 Use of the peptide gly-arg-gly-asp-asn-pro as a therapeutic agent |
| 04/02/2009 | WO2009039988A2 Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection |
| 04/02/2009 | WO2009039987A1 Use of peptide thr-thr-ser-gln-val-arg-pro-arg as a therapeutic agent |
| 04/02/2009 | WO2009039986A2 Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent |
| 04/02/2009 | WO2009039984A2 Therapeutic uses of urocortin ii and kisspeptin ( 27-54 ) |
| 04/02/2009 | WO2009039983A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039982A2 Use of gip alone or in combination with dynorphin b as a therapeutic agent |
| 04/02/2009 | WO2009039981A2 Use of (arg 8) vasopressin to treat eg s. pneumoniae infection |
| 04/02/2009 | WO2009039980A2 Use of bfgf 1-24 and optionally (arg 8) vasopressin to treat eg s. pneumoniae infection |
| 04/02/2009 | WO2009039979A1 Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
| 04/02/2009 | WO2009039978A2 Therapeutic use of neuropeptide ei and acth 7-38 and compositions thereof |
| 04/02/2009 | WO2009039977A2 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hbv infection |
| 04/02/2009 | WO2009039976A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039970A1 Use of bpp-b as a therapeutic agent |
| 04/02/2009 | WO2009039969A2 Use of a vla-4 inhibitor tetrapeptide, alone or in combination with bpp-b, as a therapeutic agent |
| 04/02/2009 | WO2009039968A2 Use of angiotensin iii as a therapeutic agent in the treatment of eg hbv infection |
| 04/02/2009 | WO2009039966A2 Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection |
| 04/02/2009 | WO2009039963A1 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent |
| 04/02/2009 | WO2009039960A1 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-ard-gly-asp-asn-pro-oh as a therapeutic agent |